Evidence map›Paper›PMID 39253288›Full record

ArticleFrontiers in public health2024

Global hepatitis B and D community advisory board: expectations, challenges, and lessons learned.

Fiona Borondy-Jenkins, Bright Ansah, Jacki Chen, Amanda Goldring, Yasmin Ibrahim, Shaibu Issa, Silvana Lesidrenska, Tanya Machado, Holly Moore, Richard Njouom and 5 more

Abstract read
In one paragraph

Article in Frontiers in public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Fiona Borondy-Jenkins *Hepatitis B Foundation, Doylestown, PA, United States.
Bright AnsahHepatitis B Foundation, Doylestown, PA, United States.
Jacki ChenHepatitis B Foundation, Doylestown, PA, United States.
Amanda GoldringHepatitis B Foundation, Doylestown, PA, United States.
Yasmin Ibrahim *Hepatitis B Foundation, Doylestown, PA, United States.
Shaibu IssaHepatitis B Foundation, Doylestown, PA, United States.
Silvana LesidrenskaHepatitis B Foundation, Doylestown, PA, United States.
Tanya Machado *Hepatitis B Foundation, Doylestown, PA, United States.
Holly Moore *Hepatitis B Foundation, Doylestown, PA, United States.
Richard NjouomHepatitis B Foundation, Doylestown, PA, United States.
Prince OkinedoHepatitis B Foundation, Doylestown, PA, United States.
Rhea RachoHepatitis B Foundation, Doylestown, PA, United States.
Lori ScottHepatitis B Foundation, Doylestown, PA, United States.
Beatrice Zovich *Hepatitis B Foundation, Doylestown, PA, United States.
Chari Cohen *Hepatitis B Foundation, Doylestown, PA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Community Advisory Boards (CABs) play an important role in developing and delivering patient-centered care. However, the impact of participation on CAB members has not been well studied, particularly on the global scale. In 2022, the Hepatitis B Foundation (HBF) convened the first global hepatitis B and hepatitis delta CAB with 23 members from 17 countries, representing six out of the seven World Health Organization (WHO) regions, and countries with the largest hepatitis B and hepatitis delta disease burden. Methods: To reflect on the process of assembling an effective and motivated CAB and assess the impact on CAB participants, three virtual focus group sessions were held with 16 participants in July and August 2023. Sessions were recorded and transcribed. Questions focused on motivations for joining the CAB, membership experiences, and lessons learned. Grounded theory analysis was used to generate hypotheses about reasons for CAB members' participation, as well as challenges and suggestions. Qualitative analysis using inductive reasoning identified key themes within responses. Transcripts were independently analyzed by a primary and secondary coder. Results: Motivations for joining the CAB included participants' desire to advocate for people living with hepatitis B and hepatitis delta, and other altruistic factors. Participants reflected that through CAB membership, they gained networking and advocacy opportunities and enhanced their hepatitis B- and hepatitis delta-related knowledge. Challenges participants experienced were related to time, physical limitations, and stigma. Finally, participants discussed their limited direct engagement with drug developers and proposed ways the CAB can increase interactions with stakeholders going forward. Discussion: Based on participants' assessments, establishing a global CAB for stigmatized infectious diseases is worth the effort. Regular internal review of community advisory boards' structure and performance is critical to ensure the CAB is fulfilling its mission.

Indexed as

Advisory CommitteesFocus GroupsGlobal HealthHepatitis BAdultCommunity ParticipationFemaleHumansMaleMiddle AgedMotivationQualitative ResearchWorld Health Organizationclinical trial designcommunity empowermentdrug developmentglobal advisory boardhepatitis Bhepatitis Dpatient centricityresearch participation

Identifiers

PMID39253288
PMCPMC11381374

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.